Jeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Jeffrey Sherman sold 42,232 shares of the stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $7.92, for a total value of $334,477.44. Following the sale, the director owned 219,188 shares of the company’s stock, valued at $1,735,968.96. This represents a 16.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.83 on Friday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $8.02. The stock has a 50 day simple moving average of $5.87 and a two-hundred day simple moving average of $4.99. The stock has a market cap of $1.26 billion, a P/E ratio of -37.28 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The business had revenue of $67.71 million during the quarter, compared to analysts’ expectations of $64.58 million. Sell-side analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on XERS. Oppenheimer raised their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday, May 9th. Leerink Partners increased their target price on Xeris Biopharma from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Tuesday, August 19th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Finally, HC Wainwright initiated coverage on Xeris Biopharma in a research note on Tuesday, August 12th. They set a “buy” rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $7.08.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $34,000. Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $45,000. Two Sigma Advisers LP purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $47,000. Aquatic Capital Management LLC purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $50,000. Finally, Apella Capital LLC purchased a new stake in shares of Xeris Biopharma in the first quarter valued at approximately $55,000. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.